Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0FC9J
|
|||
Drug Name |
PMID28394193-Compound-51
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
BRISTOL-MYERS SQUIBB COMPANY
|
|||
Structure |
Download2D MOL |
|||
Formula |
C26H31Cl2N3O4
|
|||
Canonical SMILES |
CC1=CC(=C(C(=O)N1)CN2CCC3=C(C=C(C(=C3C2=O)Cl)C(C4CCN(CC4)C(=O)C)OC)Cl)C
|
|||
InChI |
1S/C26H31Cl2N3O4/c1-14-11-15(2)29-25(33)20(14)13-31-10-7-18-21(27)12-19(23(28)22(18)26(31)34)24(35-4)17-5-8-30(9-6-17)16(3)32/h11-12,17,24H,5-10,13H2,1-4H3,(H,29,33)
|
|||
InChIKey |
PCBQYEOJXRGLFI-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Enhancer of zeste homolog 2 (EZH2) | Target Info | Inhibitor | [1] |
Target's Patent Info | Enhancer of zeste homolog 2 (EZH2) | Target's Patent Info | [1] | |
KEGG Pathway | MicroRNAs in cancer | |||
NetPath Pathway | IL2 Signaling Pathway | |||
Reactome | PRC2 methylates histones and DNA | |||
Oxidative Stress Induced Senescence | ||||
PKMTs methylate histone lysines | ||||
WikiPathways | Interactome of polycomb repressive complex 2 (PRC2) | |||
Endoderm Differentiation | ||||
Integrated Pancreatic Cancer Pathway | ||||
Histone Modifications | ||||
Cell Differentiation - meta | ||||
miRs in Muscle Cell Differentiation | ||||
miR-targeted genes in muscle cell - TarBase | ||||
miR-targeted genes in lymphocytes - TarBase | ||||
miR-targeted genes in epithelium - TarBase |
References | Top | |||
---|---|---|---|---|
REF 1 | EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.